Literature DB >> 17196186

Effects of ex vivo transduction of mesencephalic reaggregates with bcl-2 on grafted dopamine neuron survival.

Caryl E Sortwell1, William J Bowers, Scott E Counts, Mark R Pitzer, Matthew F Fleming, Susan O McGuire, Kathleen A Maguire-Zeiss, Howard J Federoff, Timothy J Collier.   

Abstract

Survival rates of dopamine (DA) neurons grafted to the denervated striatum are extremely poor (5-20%). Gene transfer of survival promoting factors, such as the anti-apoptotic protein bcl-2, to mesencephalic DA neurons prior to transplantation (ex vivo transduction) offers a novel approach to increase graft survival. However, specific criteria to assess the efficacy of various vectors must be adhered to in order to reasonably predict successful gene transfer with appropriate timing and levels of protein expression. Cell culture results utilizing three different herpes simplex virus (HSV) vectors to deliver the reporter beta-galactosidase gene (lacZ) indicate that transduction of mesencephalic cells with a helper virus-free HSV amplicon (HF HSV-TH9lac) that harbors the 9-kb tyrosine hydroxylase (TH) promoter to drive lacZ gene expression elicits the transduction of the highest percentage (approximately 50%) of TH-immunoreactive (THir) neurons without significant cytotoxic effects. This transduction efficiency and limited cytotoxicity was superior to that observed following transduction with helper virus-containing HSV (HC HSVlac) and helper virus-free HSV amplicons (HF HSVlac) expressing lacZ under the transcriptional control of the HSV immediate-early 4/5 gene promoter. Subsequently, we assessed the ability of HSV-TH9lac and the bcl-2 expressing HSV-TH9bcl-2 amplicon to transduce mesencephalic reaggregates. Although an increase in bcl-2 and beta-galactosidase protein was induced by transduction, amplicon-mediated overexpression of bcl-2 did not lead to an increase in grafted THir neuron number. Even with highly efficient viral vector-mediated transduction, our results demonstrate that ex vivo gene transfer of bcl-2 to mesencephalic reaggregates is ineffective in increasing grafted DA neuron survival.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196186      PMCID: PMC2041451          DOI: 10.1016/j.brainres.2006.11.079

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  49 in total

1.  Discordance between expression and genome transfer titering of HSV amplicon vectors: recommendation for standardized enumeration.

Authors:  W J Bowers; D F Howard; H J Federoff
Journal:  Mol Ther       Date:  2000-03       Impact factor: 11.454

2.  Patterns of cell death and dopaminergic neuron survival in intrastriatal nigral grafts.

Authors:  M Emgård; J Karlsson; O Hansson; P Brundin
Journal:  Exp Neurol       Date:  1999-11       Impact factor: 5.330

3.  Intracerebral grafting of dopamine neurons. Experimental basis for clinical trials in patients with Parkinson's disease.

Authors:  P Brundin; R E Strecker; O Lindvall; O Isacson; O G Nilsson; G Barbin; A Prochiantz; C Forni; A Nieoullon; H Widner
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

4.  Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats.

Authors:  Eleonora Maries; Jeffrey H Kordower; Yaping Chu; Timothy J Collier; Caryl E Sortwell; Eliza Olaru; Kathleen Shannon; Kathy Steece-Collier
Journal:  Neurobiol Dis       Date:  2005-08-10       Impact factor: 5.996

5.  Diminished survival of mesencephalic dopamine neurons grafted into aged hosts occurs during the immediate postgrafting interval.

Authors:  C E Sortwell; M D Camargo; M R Pitzer; S Gyawali; T J Collier
Journal:  Exp Neurol       Date:  2001-05       Impact factor: 5.330

6.  Oligodendrocyte-type 2 astrocyte-derived trophic factors increase survival of developing dopamine neurons through the inhibition of apoptotic cell death.

Authors:  C E Sortwell; B F Daley; M R Pitzer; S O McGuire; J R Sladek; T J Collier
Journal:  J Comp Neurol       Date:  2000-10-09       Impact factor: 3.215

7.  GDNF reduces drug-induced rotational behavior after medial forebrain bundle transection by a mechanism not involving striatal dopamine.

Authors:  J L Tseng; E E Baetge; A D Zurn; P Aebischer
Journal:  J Neurosci       Date:  1997-01-01       Impact factor: 6.167

Review 8.  Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease.

Authors:  K S Bankiewicz; S E Leff; D Nagy; S Jungles; J Rokovich; K Spratt; L Cohen; M Libonati; R O Snyder; R J Mandel
Journal:  Exp Neurol       Date:  1997-03       Impact factor: 5.330

9.  Herpes simplex virus type 1 amplicon vectors with glucocorticoid-inducible gene expression.

Authors:  B Lu; H J Federoff
Journal:  Hum Gene Ther       Date:  1995-04       Impact factor: 5.695

10.  Embryonic mesencephalic grafts increase levodopa-induced forelimb hyperkinesia in parkinsonian rats.

Authors:  Kathy Steece-Collier; Timothy J Collier; Paul D Danielson; Roger Kurlan; David M Yurek; John R Sladek
Journal:  Mov Disord       Date:  2003-12       Impact factor: 10.338

View more
  4 in total

Review 1.  How to improve the survival of the fetal ventral mesencephalic cell transplanted in Parkinson's disease?

Authors:  Jia Liu; Hong-Yun Huang
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

Review 2.  Ion channels in regulation of neuronal regenerative activities.

Authors:  Dongdong Chen; Shan Ping Yu; Ling Wei
Journal:  Transl Stroke Res       Date:  2014-01-08       Impact factor: 6.829

3.  Effects of herpes simplex virus amplicon transduction on murine dendritic cells.

Authors:  Yahui Grace Chiu; William J Bowers; Seung T Lim; Deborah A Ryan; Howard J Federoff
Journal:  Hum Gene Ther       Date:  2009-05       Impact factor: 5.695

4.  An integral approach to the etiopathogenesis of human neurodegenerative diseases (HNDDs) and cancer. Possible therapeutic consequences within the frame of the trophic factor withdrawal syndrome (TFWS).

Authors:  Salvador Harguindey; Gorka Orive; Ramón Cacabelos; Enrique Meléndez Hevia; Ramón Díaz de Otazu; Jose Luis Arranz; Eduardo Anitua
Journal:  Neuropsychiatr Dis Treat       Date:  2008-12       Impact factor: 2.570

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.